ClinicalTrials.gg
CompletedNCT06453265Updated Dec 18, 2025

A Study to Assess the Abuse Potential of Intranasal Cebranopadol

A Phase 1 interventional study of Cebranopadol- 600 ug and Cebranopadol- 800ug in Abuse, Drug, sponsored by Tris Pharma, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-18.

Sponsored by Tris Pharma, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2024, 2 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,589 studies in Substance-Related Disorders with a site in United States — 249 open to participants now, 313 under way, 4 of them phase 3. Substance-Related Disorders · United States.

Enrollment
1,028th of 1,447
48 · median 104
Started
2024
with 73 others
Phase 1
131 of 1,589
14 open now
Registered
1,378th of 1,589
by date

Among the 1,589 studies in Substance-Related Disorders with a site in United States, this one is the 1,028th largest by enrollment of the 1,447 interventional ones that give a count, is one of 74 that started in 2024, is one of 131 in phase 1, and was the 1,378th registered.

Substance-Related Disorders

2,241 studies on the registry are indexed under Substance-Related Disorders; 409 are open to participants now.

Browse Substance-Related Disorders studies →

Open to participants now

249 of the 1,589 studies in Substance-Related Disorders with a site in United States are open now. Recruiting first, the newest first:

244 more — sign in →

All 249 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 264 Substance-Related Disorders studies recruiting now, 129 (49%) set no upper age limit and 117 (44%) stop at 75 or younger; 55 take children under 18; 89 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,589 studies in Substance-Related Disorders with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study to Assess the Abuse Potential of Intranasal Cebranopadol Compared to Oxycodone and Placebo in Healthy, Nondependent Recreational Opioid Users.

Read the detailed description

This study will be conducted to examine the intranasal abuse potential of cebranopadol compared with oxycodone HCl IR and placebo in recreational opioid users with intranasal experience, a Dose Escalation Phase (Part A) will first be conducted to determine a safe dose for evaluation in the Main Study (Part B).

The Dose Selection Phase (Part A) will consist of 3 phases: Screening, Treatment and Follow-up. Subjects will participate in an outpatient medical screening visit, a 4-day treatment visit and a follow-up phone call.

The Main Study (Part B) will consist of 4 phases: Screening, Qualification, Treatment and Follow-up. Subjects will participate in an outpatient screening visit, a 4-day Qualification Phase, a 30-day Treatment Phase and a follow-up phone call.

03

Conditions studied

  • Abuse, Drug

Keywords

  • Human Abuse Potential
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Experienced opioid user who meets the following criteria: (1) has used opioids for nontherapeutic purposes (i.e., for psychoactive effects) on at least 10 occasions in the year prior to Screening; (2) has used opioids at least once in the 12 weeks prior to Screening; and (3) self-reported intranasal use of drugs of abuse on at least 3 occasions in the year prior to Screening.
  • Subjects must be in good health as determined by medical history, physical examination, 12-lead and vital signs measures (pulse rate, systolic and diastolic blood pressure, respiratory rate and oxygen saturation using pulse oximetry) at Screening.
  • Subjects must be willing to comply with the requirements and restrictions of the study.

Key Exclusion Criteria:

  • Drug or alcohol dependence in the 12 months prior to Screening (except nicotine), as defined by the , 4th Edition, Text Revision (DSM-IV-TR), or any self-reported dependence or "addiction" within the subject's lifetime (except nicotine or caffeine).
  • Subjects who have ever been in treatment for substance use disorder(s) (except smoking cessation).
  • History or presence of any cardiac, psychiatric, endocrine, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, renal or other disease at Screening, which, in the opinion of the investigator, would jeopardize the safety of the subject or the validity of the study results.
  • Clinically significant abnormalities in the intranasal cavity (including a deviated septum, perforated nasal septum, rhinorrhea, or excessive sneezing) or any condition that, in the opinion of the investigator, would interfere with the study procedures, data integrity or would compromise the safety of the subject. Subjects with nasal piercings/nose rings will be required to remove them for the duration of their inpatient stay.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Dose Selection- 600ug (Part A)

    Cebranopadol 600 ug single dose

    Drug: Cebranopadol- 600 ug

  • Experimental
    Dose Selection - 800 ug (Part A)

    Cebraopadol 800 ug single dose

    Drug: Cebranopadol- 800ug

  • Experimental
    Dose Selection- 1000 ug (Part A)

    Cebranopadol 1000 ug single dose

    Drug: Cebranopadol- 1000ug

  • Active comparator
    Qualification Phase - Oxycodone (Part B)

    Oxycodone 40mg

    Drug: Qualification

  • Placebo comparator
    Qualification Phase - Placebo (Part B)

    Matching Placebo

    Drug: Qualification

  • Experimental
    Treatment Phase A- (Part B)

    -Treatment A: Cebranopadol

    Drug: Treatment A:

  • Active comparator
    Treatment Phase B- (Part B)

    \- Treatment B: Oxycodone HCl IR 40 mg

    Drug: Treatment B

  • Placebo comparator
    Treatment Phase C (Part B)

    \- Treatment C: Placebo

    Drug: Treatment C

Interventions

  • Dose ascending cohorts \- Cebranopadol 600 ug single dose

  • Dose ascending cohorts \- Cebraopadol 800 ug single dose

  • Dose ascending cohorts \- Cebranopadol 1000 ug single dose

  • DrugTreatment A:

    Cebranopadol, dose determined in Part A

  • DrugTreatment B

    Oxycodone HCl IR 40 mg

  • DrugTreatment C

    Placebo

  • DrugQualification

    Oxycodone 40mg

  • DrugQualification

    Matching Placebo

06

What researchers measure

Primary outcomes

  1. Drug Liking VAS Emax

    The primary pharmacodynamic endpoint (Drug Liking VAS Emax) will be evaluated with a linear mixed-effects model, containing treatment, period, sequence and first-order carryover as fixed effects and subject nested within sequence as random effect, using the Modified Completer Population

    Time frame: 48 hrs of Tmax for each treatment

07

Study locations

1 site
  • Ohio Clinical Trials, Inc.
    Columbus, Ohio 43212, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Nov 2024, 4 months.

Of 24 industry-sponsored phase 1 interventional studies under Substance-Related Disorders, half reached primary completion within 4 months of starting (the median); a quarter within 3 and three quarters within 9. This study's 4 months is close to that.

Counting every sponsor, half of 54 studies reached it within 12 months; a quarter within 4 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2024
First posted
Jun 11, 2024
StartActual
Jun 28, 2024
Primary completionActual
Nov 6, 2024
CompletionActual
Nov 6, 2024
Last update
Dec 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06453265
Lead sponsor
Tris Pharma, Inc.
Responsible party
Sponsor
First posted
Jun 11, 2024
Start date
Jun 28, 2024
Primary completion
Nov 6, 2024
Completion
Nov 6, 2024
Last update
Dec 18, 2025

Study contacts

Angela Eakin, MD
principal investigator · Ohio Clinical Trials

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cebranopadol

Start the discussion